Recombinant human PD-1 antibody herpes simplex virus(Xiamen University)

Primary objectives: To evaluate the safety and tolerability of intravenous administration of rHSV-1-APD1 in the treatment of patients with primary central nervous system tumors/brain metastases from solid tumors, and to determine the maximum tolerated dose (MTD)/recommended phase II clinical dose (RP2D) and dose-limiting toxicity (DLT). Secondary objectives: To evaluate the biodistribution characteristics of intravenous administration of rHSV-1-APD1. To evaluate the preliminary anti-tumor efficacy of intravenous administration of rHSV-1-APD1 in patients with primary central nervous system tumors/brain metastases from solid tumors. To evaluate the relationship between the anti-tumor efficacy of intravenous administration of rHSV-1-APD1 in the treatment of patients with primary central nervous system tumors/brain metastases from solid tumors and pharmacodynamic indicators and immunogenicity indicators. To evaluate the relationship between the safety of intravenous administration of rHSV-1-APD1 and immunogenicity indicators.